Literature DB >> 15239395

Diverse clinical applications using advantages of allogeneic peripheral blood stem cell transplantation.

Sang Kyun Sohn1, Jong Gwang Kim, Dong Hwan Kim, Jin Ho Baek, Kyu Bo Lee.   

Abstract

The diverse clinical applications of allogeneic peripheral blood stem cells based on use of their advantages are summarized. It is apparent that more stem cells and T-lymphocytes can be harvested by mobilization treatment with cytokines from healthy donors in allogeneic peripheral blood stem cell transplantation (PBSCT) than in bone marrow transplantation. It is also clear that a stronger graft-versus-tumor effect can be induced with allogeneic PBSCT than with bone marrow transplantation. One merit of allogeneic PBSCT is that it allows clinicians to design diverse clinical applications. It would appear that allogeneic PBSCT may be preferable in special clinical settings, such as advanced hematological malignancies, situations requiring a strong graft-versus-tumor effect, nonmyeloablative stem cell transplantation, and situations requiring a megadose of stem cells. Cytokine-primed peripheral blood stem cells can also be used for adoptive immunotherapy, such as a nonprimed donor lymphocyte infusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15239395     DOI: 10.1532/ijh97.a10313

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  42 in total

1.  GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.

Authors:  S K Sohn; J G Kim; K W Seo; Y S Chae; J T Jung; J S Suh; K B Lee
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

2.  Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation.

Authors:  D Zeng; S Dejbakhsh-Jones; S Strober
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

3.  PBPC as an alternative cell therapy for post-transplant relapse in CML.

Authors:  M M Abecasis; A Guimarães; A Machado; L Vieira; G Boavida; M Jorge
Journal:  Bone Marrow Transplant       Date:  1998-09       Impact factor: 5.483

4.  Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia.

Authors:  O Ringdén; M Labopin; A Bacigalupo; W Arcese; U W Schaefer; R Willemze; H Koc; D Bunjes; E Gluckman; V Rocha; A Schattenberg; F Frassoni
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

5.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

Authors:  John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

6.  Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.

Authors:  Sang-Kyun Sohn; Jin-Tae Jung; Dong-Hwan Kim; Nan-Young Lee; Kwang-Woon Seo; Yee-Soo Chae; Soung-Won Park; Jong-Gwang Kim; Jang-Soo Suh; Kyu-Bo Lee
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

7.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

8.  Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.

Authors:  Jose A Perez-Simon; Maria Diez-Campelo; Rodrigo Martino; Anna Sureda; Dolores Caballero; Consuelo Canizo; Salut Brunet; Albert Altes; Lourdes Vazquez; Jordi Sierra; Jesus F San Miguel
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

9.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

10.  Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation.

Authors:  Derek L Stirewalt; Katherine A Guthrie; Lan Beppu; Eileen M Bryant; Kris Doney; Ted Gooley; Frederick R Appelbaum; Jerald P Radich
Journal:  Biol Blood Marrow Transplant       Date:  2003-03       Impact factor: 5.742

View more
  2 in total

1.  The human-sheep chimeras as a model for human stem cell mobilization and evaluation of hematopoietic grafts' potential.

Authors:  Graça Almeida-Porada; Christopher Porada; Nicole Gupta; Ali Torabi; David Thain; Esmail D Zanjani
Journal:  Exp Hematol       Date:  2007-10       Impact factor: 3.084

2.  A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience.

Authors:  Serife Solmaz; Selda Kahraman; Omur Gokmen Sevindik; Celal Acar; Munire Turkyilmaz; Inci Alacacioglu; Ozden Piskin; Mehmet Ali Ozcan; Hayri Guner Ozsan; Bulent Undar; Fatih Demirkan
Journal:  Indian J Hematol Blood Transfus       Date:  2018-01-23       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.